Kenneth Lee
Kenneth specialises in corporate mergers and acquisitions (private treaty and regulated), private equity, funds management and equity capital markets (IPOs and capital raisings). He has developed expertise in ESG and its key role in investors’ decision making, and works with clients to integrate sustainability considerations into their corporate strategies and investments. He has authored multiple publications on ESG (including in a UK journal with international readership) which may be viewed via his LinkedIn profile.
Kenneth is best known for his approachability, clear communication and problem solving skills. He has advised on numerous transactions for both investors and investees across industries including agribusiness, health and medtech, fintech, property, software and resources. He is fluent in English and Chinese, and has clients from Australia, South-east Asia, China and the US.
Kenneth is a Monash University alumni with a Bachelor of Laws (Honours) and Bachelor of Science. He was awarded the faculty prize for constitutional law and his research thesis received a High Distinction. He holds a Certificate in Governance Practice from the Governance Institute of Australia.
Experience
Kenneth’s experience includes advising:
- Whispir Limited on its $163 million IPO and ASX listing and its subsequent $45.9 million institutional placement and share purchase plan;
- Eagle Health Holdings Limited on its $125 million IPO and ASX listing;
- Clean Seas Seafood Limited on its $25 million institutional two tranche placement and secondary listing on a European exchange;
- Nuchev Limited on its entitlement offer and placement to a key strategic investor (including exclusive distributor arrangements);
- Alliance Resources Limited on its takeover response, compulsory acquisition and subsequent delisting from ASX;
- Numerous ASX listed clients on capital raisings, compliance with the ASX Listing Rules and the Corporations Act and corporate governance;
- Australian fintech start up on multiple capital raisings including its $25 million Series A and $32.5 million Series B, involving key investors such as Mastercard and Westpac and various venture capital funds;
- A national private equity group on multiple investments including its underwriting of a $23.4 million placement of preference shares in a public company in the sensitive health data and prescriptions industry;
- An international consortium of investors on their acquisition of 89.5% of Genea Limited for approximately $300 million via a scheme; and
- Numerous private clients on business, share and asset acquisitions and disposals.